Clinical Impact of Vagus Nerve Stimulation Therapy in Severe Epilepsy

Generalized tonic-clonic seizures represent the most devastating manifestation of drug-resistant epilepsy due to substantial health risks. Consequently, patients experiencing recurrent convulsive episodes face heightened rates of physical injury, cognitive impairment, status epilepticus, and sudden unexpected death. Although modern antiseizure medications provide the primary line of medical treatment, approximately one-third of individuals fail to achieve adequate seizure control. Furthermore, many refractory patients are ineligible for curative resective neurosurgery due to diffuse, multifocal, or eloquent epileptogenic networks. Therefore, clinicians require durable, non-pharmacological interventions that effectively suppress intractable convulsions. Vagus nerve stimulation therapy has become an indispensable adjunctive approach for managing these complex clinical scenarios. By transmitting programmed electrical impulses to the left vagus nerve, this system modulates subcortical and thalamocortical pathways, thereby disrupting seizure synchronization. Over past decades, device-based neuromodulation has demonstrated safety across diverse patient cohorts. However, evaluating prospective real-world registries remains vital to establish long-term clinical durability and functional recovery. Notably, emerging multi-center evidence demonstrates that electrical neuromodulation achieves profound reductions in convulsive seizure burden. Ultimately, incorporating advanced device therapies addresses a critical unmet therapeutic need for refractory epilepsy patients across global neurological practice.

Design and Cohort Characteristics of the CORE-VNS Registry

The prospective, multicenter CORE-VNS observational study was established to capture real-world clinical outcomes following device implantation. Specifically, investigators tracked both seizure frequency and comprehensive patient-reported outcome measures across international epilepsy centers. The formal protocol collected longitudinal data at baseline and at 3, 6, 12, 24, and 36 months post-implantation. For this targeted interim analysis, researchers evaluated 115 participants who presented with generalized tonic-clonic seizures at baseline. This cohort represents a severely refractory population with prolonged disease duration before surgical intervention. In fact, participants experienced a median duration of ten years between their initial epilepsy diagnosis and neuromodulation implantation. Furthermore, approximately half of the evaluated cohort consisted of pediatric patients under 18 years of age. Notably, ninety-four percent of participants had never undergone prior resective epilepsy surgery. This demographic feature indicates that clinicians preferentially selected neuromodulation over irreversible brain tissue resections. Patients recorded seizure activity during a three-month pre-implantation baseline window to ensure reliable comparative data. In addition, treating neurologists documented medication adjustments and adverse events at every follow-up. Consequently, the 24-month interim findings provide valuable evidence regarding therapeutic durability in routine clinical practice.

Sustained Seizure Reductions and Convulsive Freedom at 24 Months

Evaluating long-term seizure frequency remains the primary benchmark for measuring the true clinical efficacy of adjunctive neurostimulation devices. In the CORE-VNS cohort, participants demonstrated rapid and sustained improvements following device implantation. After 12 months of active stimulation, patients experienced a median generalized tonic-clonic seizure reduction of 73.9%. Even more remarkably, 37% of evaluated individuals reported complete freedom from generalized tonic-clonic seizures during the three months preceding the 12-month visit. These clinical benefits persisted and strengthened over extended follow-up. At the 24-month milestone, investigators documented a median convulsive seizure reduction of 77%. Furthermore, 42.6% of participants achieved complete seizure freedom from generalized tonic-clonic episodes during the three months prior to the 24-month evaluation. This sustained response confirms that therapeutic efficacy does not wane with continuous long-term stimulation. Instead, progressive network modulation provides enduring protection against secondary generalization and primary convulsive propagation. For clinicians managing treatment-resistant epilepsy, achieving convulsive seizure freedom in over forty percent of patients represents a major clinical milestone. Consequently, sustained reductions in generalized tonic-clonic episodes directly decrease emergency hospitalizations and substantially mitigate the catastrophic risk of sudden unexpected death.

Marked Reductions in Postictal Severity and Functional Burden

Beyond numerical seizure frequency, postictal severity profoundly influences patient independence, caregiver burden, and overall quality of life. Severe convulsive seizures typically produce debilitating confusion, severe exhaustion, headaches, and prolonged autonomic instability. Fortunately, the CORE-VNS registry systematically recorded qualitative improvements in postictal burden alongside quantitative seizure diaries. At baseline, 52.8% of participants described the postictal severity of their most debilitating seizure as severe or very severe. Following 12 months of adjunctive neurostimulation, this proportion dropped dramatically to 25.3%, representing a swift and clinically meaningful reduction. Furthermore, this positive improvement remained stable over time, with only 26.3% of participants reporting severe postictal distress after 24 months. Therefore, neuromodulation appears to attenuate the neurobiological intensity of breakthrough seizures when they occur. By shortening the postictal recovery window, patients resume daily functional activities much sooner following an episode. In addition, reducing postictal respiratory depression and autonomic dysfunction provides vital physiological protection against life-threatening seizure complications. Caregivers also experience substantial relief from decreased constant monitoring and fewer emergency interventions. Thus, mitigating postictal severity constitutes a vital holistic benefit of long-term vagus nerve stimulation therapy.

Safety Profile and Practical Considerations for Neurologists

When evaluating implantable neuromodulation, physicians must evaluate device safety and potential interactions with concurrent pharmacological regimens. Notably, the overall antiseizure medication load of participants did not change significantly throughout the 24-month follow-up period. Consequently, the observed reductions in seizure frequency stemmed directly from device therapy rather than aggressive drug escalation. Maintaining a stable pharmacological baseline prevents additive cognitive side effects, hepatotoxicity, and adverse drug interactions. Furthermore, recorded adverse events aligned with the established safety profile documented in previous epilepsy trials. The most common stimulation-related side effects included voice alterations, coughing, throat paresthesia, and transient dyspnea during active pulse cycles. Fortunately, these adverse events were generally mild and responded well to stimulation parameter adjustments or natural physiological habituation. No unexpected device failures or life-threatening stimulation complications were reported during the study. Therefore, adjunctive neuromodulation demonstrates an exceptional benefit-to-risk ratio in complex patients. Neurologists should identify potential candidates early once medical resistance is established rather than delaying device referral for years. Ultimately, integrating electrical neuromodulation into comprehensive management protocols delivers durable, safe, and life-changing seizure control for drug-resistant epilepsy.

How does vagus nerve stimulation therapy reduce generalized tonic-clonic seizures?

The implanted pulse generator delivers scheduled electrical signals along the left vagus nerve to brainstem nuclei, particularly the nucleus tractus solitarius. Subsequently, these afferent signals project to the thalamus and cerebral cortex. This continuous network modulation desynchronizes epileptogenic activity, elevates seizure thresholds, and effectively suppresses seizure propagation across bilateral hemispheres.

Which clinical candidates benefit most from vagus nerve stimulation therapy?

Ideal candidates include adults and pediatric patients diagnosed with drug-resistant epilepsy who experience persistent convulsive seizures despite adequate trials of two or more antiseizure medications. Neurologists particularly favor neuromodulation when surgical resection is unfeasible, contraindicated, or ineffective, as well as in patients presenting with diffuse or multifocal epileptogenic zones.

What are the primary adverse events associated with this device therapy?

The most common adverse events include transient hoarseness, throat discomfort, cough, voice alterations, and mild dyspnea occurring primarily during active stimulation delivery. Clinicians typically manage these stimulation-related effects by adjusting device programming parameters, modifying output current, or allowing physiological habituation, without needing surgical revision or device removal.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Suller Marti A et al. Reduction of generalized tonic-clonic seizures following vagus nerve stimulation therapy: CORE-VNS Study 24-month follow-up. Epilepsia. 2025 Jul. doi: 10.1111/epi.18371. PMID: 40167365.

Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-319.

Ryvlin P, Jehi L, Blümcke I, et al. Vagus nerve stimulation for epilepsy: Clinical evidence and potential mechanisms. Lancet Neurol. 2021;20(12):1004-1018.